measures

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedemain Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

June 14, 2025 10:48 ET  | Source: Celldex Therapeutics, Inc. 77% of patients (150 mg Q4W) treated with barzolvolimab who…

1 month ago

Eternal’s Initiatives to Support Delivery Partners during the Heatwave

NEW DELHI, June 12, 2025 /PRNewswire/ -- In light of the ongoing extreme weather conditions, Eternal Ltd. (formerly Zomato Ltd.)…

1 month ago